Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.86 |
| ▸ | JAK3 | P52333 | 9/20 | 0.72 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | AKT2 | P31751 | 2/20 | 0.65 |
| ▸ | GSK3B | P49841 | 2/20 | 0.65 |
| ▸ | KIT | P10721 | 1/20 | 0.65 |
| ▸ | JAK2 | O60674 | 9/20 | 0.62 |
| ▸ | JAK1 | P23458 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15170325 | 1.00 | DOT1L (0.86) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL9966955 | 0.92 | LCK (0.75) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL3586517 | 0.84 | JAK3 (0.65) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL10075565 | 0.84 | JAK3 (0.65) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL3951434 | 0.84 | JAK3 (0.65) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL15169950 | 0.84 | JAK3 (0.65) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL2021330 | 0.84 | JAK3 (1.00) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL10079358 | 0.84 | JAK3 (1.00) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL2019902 | 0.83 | JAK3 (0.62) | DOT1LJAK3LCKAKT2GSK3B | |
| SCHEMBL15178732 | 0.82 | DOT1L (0.85) | DOT1LJAK3LCKAKT2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-08-06 | — | — | US | disclosed |
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-08-06 | — | — | US | disclosed |
| US-10111875-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHINSON MEDIPHARMA LIMITED (CN) | 2018-10-30 | — | — | US | disclosed |
| EP-2606051-B1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| EP-2606051-B1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED | 2016-08-11 | — | — | US | disclosed |
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED | 2016-08-11 | — | — | US | disclosed |
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED | 2016-08-11 | — | — | US | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| WO-2012022265-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
| WO-2012022045-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228443-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | DOT1L 1330/4885JAK3 3/4885LCK 7/4885 |
| US-10111875-B2 | Pyrrolopyrimidine compounds and uses thereof | JAK2, JAK1, JAK3 | DOT1L 1330/4885JAK3 3/4885LCK 7/4885 |
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | JAK2, JAK1, JAK3 | DOT1L 1330/4885JAK3 3/4885LCK 7/4885 |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | DOT1L 1330/4885JAK3 3/4885LCK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.